AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Antigenics Receives Milestone Payment from Elan Corp. for QS-21.(Brief Article)
2002 JAN 16 - (NewsRx.com & NewsRx.net) -- Antigenics, Inc., (AGEN) has received a milestone payment from Elan Corp. (ELN) for its leading immune-stimulating adjuvant, QS-21, the only adjuvant utilized in an experimental Alzheimer disease vaccine under clinical development by Elan and American Home Products (AHP).
The milestone payment was based on the advancement of the vaccine, known as "AN-1792", to a Phase IIA trial after the product showed positive results in Phase I studies.
Antigenics' QS-21 adjuvant - a compound used in combination with vaccines to boost immune responses - is one of the most widely used and well-characterized immune adjuvants under development. QS-21 is included in a variety of products being developed by the world's leading pharmaceutical companies for hepatitis B, malaria, HIV, cancer, respiratory viruses and Alzheimer disease.
Elan and AHP are ...
- MDS Harris Expanding Phase IIa Capabilities.
- Press release article from: PR Newswire January 12, 1999 700+ words
...Striving to be World-Leading provider of Phase IIa in Specific Therapeutic Areas LINCOLN...develop specific expertise in conducting Phase IIa studies for selected therapeutic areas...have been revealed much earlier during Phase IIa studies," Curtis said. "As a result...
- CytRx Successfully Completes Patient Dosing and Follow-Up in Phase IIa Clinical...
- Press release article from: Business Wire July 24, 2006 700+ words
...up with arimoclomol in the Company's Phase IIa clinical trial for the treatment of amyotrophic...sclerosis (ALS or Lou Gehrig's disease). Phase IIa patients were evaluated while receiving...expects to complete data analysis of the Phase IIa trial and announce final results early...
- ESBATech's Antibody Fragment ESBA105 Enters Phase IIa in Uveitis Study.
- Press release article from: PR Newswire February 24, 2009 700+ words
...today announced the initiation of a Phase IIa study in patients with acute anterior...major mediator of inflammation. The Phase IIa trial is being conducted at several uveitis...unilateral anterior uveitis. With this Phase IIa study in uveitis and recently announced...
- MEMORY FALLS AS MEM 1003 MISSES IN PHASE IIA AD TRIAL.
- Magazine article from: BIOWORLD Today Morrison, Trista October 16, 2007 700+ words
...Staff Writer Seven months after failing a Phase IIa trial in bipolar disorder, Memory Pharmaceuticals Corp.'s MEM 1003 also missed in a Phase IIa trial in Alzheimer's disease. Shares...in bipolar disorder after the previous Phase IIa trial missed its primary and secondary...
- CytRx Completes Enrollment in Phase IIa Clinical Trial for ALS; Final Phase IIa...
- Press release article from: Business Wire April 4, 2006 700+ words
...expects to report final data from this Phase IIa trial in the third quarter of this year...trial allows patients who complete our Phase IIa trial, even those previously treated...double-blind, placebo-controlled Phase IIa trial is being conducted at 10 centers...
- Centaur Pharmaceuticals Announces Interim Phase IIa Data in AIDS Dementia.
- Press release article from: PR Newswire October 19, 2000 700+ words
...for the AIDS dementia complex (ADC) Phase IIa clinical study of Centaur's compound...1189 are expected in early 2001. The Phase IIa study was designed to determine the safety...initiated disease, was evaluated in the Phase IIa study using neurological, neuropsychological...
- Arris Releases Final Data on Phase IIa Study, Receives Regulatory Approval for...
- Press release article from: Business Wire September 25, 1996 700+ words
...today announced that final data from a Phase IIa study of its tryptase inhibitor, APC...Arris also announced that a follow-on Phase IIa study has been initiated with patient...Southampton, will conduct the study. Final Phase IIa Data Summarized "An analysis of the...
- Idenix Reports Interim Analysis of a Phase IIa Clinical Trial of Valopicitabine...
- Press release article from: PR Newswire January 10, 2005 700+ words
...treatment of hepatitis C. In this phase IIa trial, patients are randomized...interim data, we have extended this phase IIa trial to 6 months in order to investigate longer duration treatment." Phase IIa Trial Design and 12 Week Interim...
Source: HighBeam Research, Antigenics Receives Milestone Payment from Elan Corp. for...